18,406 Shares in Celgene Co. (CELG) Acquired by First Hawaiian Bank

First Hawaiian Bank acquired a new position in Celgene Co. (NASDAQ:CELG) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 18,406 shares of the biopharmaceutical company’s stock, valued at approximately $1,647,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CELG. Financial Gravity Wealth Inc. purchased a new position in shares of Celgene in the first quarter worth about $417,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp purchased a new position in Celgene during the 1st quarter valued at about $767,000. Moors & Cabot Inc. increased its holdings in Celgene by 34.9% during the 1st quarter. Moors & Cabot Inc. now owns 7,392 shares of the biopharmaceutical company’s stock valued at $659,000 after purchasing an additional 1,914 shares during the period. CIBC World Markets Inc. increased its holdings in Celgene by 16.2% during the 1st quarter. CIBC World Markets Inc. now owns 160,349 shares of the biopharmaceutical company’s stock valued at $14,305,000 after purchasing an additional 22,406 shares during the period. Finally, Catalyst Capital Advisors LLC purchased a new position in Celgene during the 1st quarter valued at about $477,000. Hedge funds and other institutional investors own 73.11% of the company’s stock.

Shares of CELG opened at $84.28 on Thursday. The company has a current ratio of 1.52, a quick ratio of 1.40 and a debt-to-equity ratio of 5.76. Celgene Co. has a 52 week low of $74.13 and a 52 week high of $139.40. The company has a market capitalization of $62.94 billion, a PE ratio of 12.32, a P/E/G ratio of 0.54 and a beta of 1.30.

Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, July 26th. The biopharmaceutical company reported $2.16 EPS for the quarter, topping analysts’ consensus estimates of $2.11 by $0.05. Celgene had a return on equity of 87.28% and a net margin of 19.81%. The firm had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.70 billion. During the same period in the previous year, the firm posted $1.82 EPS. The business’s revenue for the quarter was up 16.6% compared to the same quarter last year. As a group, analysts forecast that Celgene Co. will post 7.64 earnings per share for the current fiscal year.

In related news, Director John H. Weiland purchased 5,575 shares of the company’s stock in a transaction dated Tuesday, August 7th. The shares were purchased at an average cost of $89.73 per share, with a total value of $500,244.75. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ernest Mario sold 12,000 shares of the business’s stock in a transaction that occurred on Thursday, August 9th. The stock was sold at an average price of $92.32, for a total value of $1,107,840.00. Following the completion of the sale, the director now directly owns 44,413 shares in the company, valued at $4,100,208.16. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

A number of research analysts recently issued reports on the company. BidaskClub downgraded Celgene from a “buy” rating to a “hold” rating in a report on Thursday, September 13th. Cantor Fitzgerald assumed coverage on Celgene in a report on Monday, October 1st. They set an “overweight” rating and a $100.00 price target on the stock. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Celgene in a research report on Thursday, October 11th. Morgan Stanley lifted their price objective on Celgene from $90.00 to $91.00 and gave the company an “equal weight” rating in a research report on Friday, July 13th. Finally, SunTrust Banks reaffirmed a “hold” rating and set a $101.00 price objective on shares of Celgene in a research report on Friday, July 27th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twenty have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $119.99.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Article: How to calculate the intrinsic value of a stock

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply